Ranitidine is a widely used medication in Canada, both by prescription and over the counter. A known potential human carcinogenic agent, N nitrosodimethylamine (NDMA), was detected in some batches of the medication. The objectives of this query are:
1. To estimate the extent of population exposure to ranitidine in Canada
2. To identify patients’ and prescribers’ characteristics that may influence the prescription of ranitidine, nizatidine, famotidine and cimetidine in Canada.
We will use data from four cohorts from the Canadian Partnership for Tomorrow Project (CanPath), all linked with administrative data collected by provincial Ministries of Health, to respond to this query.
Data extraction and analyses are underway. This section will be updated as our study progresses.
For more information, contact: Autumn Neville, Research Coordinator. email@example.com
This research is funded by CIHR-DSEN
Lead investigator: Dr. Sasha Bernatsky
Query 20-12 raised by Health Canada, Health Products and Food Branch (HPFB), Marketed Health Products Branch (MHPD), Health Products Surveillance & Epidemiology Bureau (HPSEB) and Marketed Pharmaceuticals Bureau (MPB)